Peyton Wong
Research Subjects
Peyton Wong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Beverly A. Teicher
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
22 shared publications - Carol J. Bult
The Jackson Laboratory
22 shared publications - David Groff
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
22 shared publications - Deryk Loo
MacroGenics (United States) 8 , Rockville, Maryland
22 shared publications - Edward Anders Kolb
Alfred I. duPont Hospital for Children, Wilmington, DE
22 shared publications - Edward Favours
UT Health Science Center at San Antonio 1 Greehey Children’s Cancer Research Institute San Antonio, Texas
22 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for hepatoblastoma models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for hepatoblastoma models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
This is the excel file with Suppl. Table S9.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
This is the excel file with Suppl. Table S9.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for MRT models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for MRT models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Western blots for models WT-12 and BT-16. Antitumor activity of vobra duo and SYD988 in WT-12 (A) and BT-16 (B) xenograft models (to support Fig. 4C and D). Vobra duo (6 mg/kg, IP) and SYD988 (6 mg/kg, IP) were each administered once on day 1. Tumors were collected at 6 hours and 48 hours after treatment. Western blot analysis was performed on tumor lysates using antibodies against B7-H3 and GAPDH (loading control).
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Western blots for models WT-12 and BT-16. Antitumor activity of vobra duo and SYD988 in WT-12 (A) and BT-16 (B) xenograft models (to support Fig. 4C and D). Vobra duo (6 mg/kg, IP) and SYD988 (6 mg/kg, IP) were each administered once on day 1. Tumors were collected at 6 hours and 48 hours after treatment. Western blot analysis was performed on tumor lysates using antibodies against B7-H3 and GAPDH (loading control).
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
CD276 gene expression profiling. Across pediatric cancers (Top); In responding (PR, CR, MCR) versus non-responding models (PD, PD1, PD2, SD), shown by tumor panel (Bottom (A-G)). “Not tested” indicates models without available in vivo activity data.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
CD276 gene expression profiling. Across pediatric cancers (Top); In responding (PR, CR, MCR) versus non-responding models (PD, PD1, PD2, SD), shown by tumor panel (Bottom (A-G)). “Not tested” indicates models without available in vivo activity data.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for Wilms tumor models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for Wilms tumor models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Immunohistochemistry (IHC) staining of B7-H3. A, H-scores for B7-H3 protein in the cell membrane, cytoplasm, and vasculature of Wilms tumor, MRT, and hepatoblastoma models. B, Representative tumor samples showing the strongest (right column) and weakest (left column) B7-H3 protein expression in Wilms tumor (second row), MRT (third row), and hepatoblastoma (bottom row) panels. C, Example of H-scoring criteria.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Immunohistochemistry (IHC) staining of B7-H3. A, H-scores for B7-H3 protein in the cell membrane, cytoplasm, and vasculature of Wilms tumor, MRT, and hepatoblastoma models. B, Representative tumor samples showing the strongest (right column) and weakest (left column) B7-H3 protein expression in Wilms tumor (second row), MRT (third row), and hepatoblastoma (bottom row) panels. C, Example of H-scoring criteria.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for RMS models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C= SYD988: 6 mg/kg, IP, Day 0 × 1.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for RMS models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C= SYD988: 6 mg/kg, IP, Day 0 × 1.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for osteosarcoma models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for osteosarcoma models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for hepatoblastoma models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
Efficacy testing summary results for hepatoblastoma models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.